Pozen Discontinues MT 100, Shifts Focus To Trexima NDA Filing
MT 100 U.S. development abandoned one day after FDA advisory committee recommends additional studies for the migraine product.
MT 100 U.S. development abandoned one day after FDA advisory committee recommends additional studies for the migraine product.